Editorial (Thematic Issue: Clinical Advances in Immuno-oncology - Progress Towards Selective Cure)

Curr Mol Pharmacol. 2016;9(3):182. doi: 10.2174/1874467208999150716103938.

Authors

Xin Liu¹, Chandra P Belani²

Affiliations

¹ Clinical Research Project Manager Penn State Hershey Cancer Institute Clinical Trial Office Room T3401 500 University Drive CH56 PO Box 850 Hershey, PA 17033-0850. xliu2@hmc.psu.edu.
² Miriam Beckner Distinguished Professor of Medicine Penn State College of Medicine Deputy Director, Penn State Hershey Cancer Institute Penn State Milton S. Hershey Medical Center 500 University Drive, CH72 Hershey, PA 17033. cbelani@psu.edu.

PMID: 26177639
DOI: 10.2174/1874467208999150716103938

No abstract available

Publication types

Editorial
Introductory Journal Article

MeSH terms

Antineoplastic Agents, Immunological / therapeutic use*
Diffusion of Innovation
Drug Discovery / trends
Humans
Immunotherapy / trends*
Medical Oncology / trends*
Molecular Targeted Therapy / trends
Neoplasms / drug therapy*
Neoplasms / immunology
Neoplasms / mortality
Neoplasms / pathology

Substances

Antineoplastic Agents, Immunological